Clinical Trials Browser

Phase 2/3 × Carcinoma, Non-Small-Cell Lung × 1 year × Clear all

NCT07100080 2026-04-16

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03637816 2026-04-15

Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer

Phase 2/3 Active not recruiting

Anorexia, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06712316 2026-04-15

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05987956 2026-04-14

Drugs-SNPs

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04929041 2026-04-13

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

Phase 2/3 Suspended

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07149649 2026-03-27

Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 2/3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04613596 2026-03-18

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07155187 2026-03-11

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03178552 2026-03-09

B-FAST

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07440290 2026-02-27

DETERMINE

Phase 2/3 Not yet recruiting

CNSEndocrineGastrointestinalGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT06236438 2026-02-23

LIVIGNO-4

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT02438722 2026-02-06

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Phase 2/3 Active not recruiting

174 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT04619797 2026-02-03

SKYSCRAPER-06

Phase 2/3 Completed

Carcinoma, Non-Small-Cell Lung

NCT07131319 2026-02-02

SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06984588 2026-01-30

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07365319 2026-01-26

TeLuRide-008

Phase 2/3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06616584 2026-01-23

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05800015 2026-01-22

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07213375 2026-01-07

DEXTER

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05768178 2025-11-24

DETERMINE

Phase 2/3 Recruiting

CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT05020769 2025-09-26

SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03653546 2025-09-10

BM

Phase 2/3 Completed

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

NCT04206072 2025-08-11

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Phase 2/3 Completed

Carcinoma, Non-Small-Cell Lung

NCT06417008 2025-08-01

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07076693 2025-07-22

Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07034326 2025-06-24

Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT00518869 2025-06-04

Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue

Phase 2/3 Terminated

Carcinoma, Non-Small-Cell Lung, Fatigue

NCT05096663 2025-05-15

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms